|Bid||9.81 x 900|
|Ask||9.92 x 1000|
|Day's range||9.70 - 9.95|
|52-week range||7.34 - 58.37|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
SAN DIEGO, June 23, 2021--The suit alleges defendants issued false statements re Frequency Therapeutics business & prospects, resulting in its stock trading at inflated prices.
NEW YORK, Jun 18, 2021--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Frequency Therapeutics, Inc. ("Frequency" or "the Company") (NASDAQ: FREQ) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Frequency securities between November 16, 2020 and March 22, 2021, (the "Class Period"). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/fr
LOS ANGELES, Jun 17, 2021--Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming August 2, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Frequency Therapeutics, Inc. ("Frequency" or "the Company") (NASDAQ: FREQ) common stock between November 16, 2020 and March 22, 2021, inclusive (the "Class Period").